FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280591010> ?p ?o ?g. }

• W4280591010 endingPage "178" @default.
• W4280591010 startingPage "166" @default.
• W4280591010 abstract "An optimal treatment strategy using oxaliplatin and bevacizumab for metastatic colorectal cancer has not been defined. We investigated whether the sequential treatment using fluoropyrimidines with bevacizumab followed by the addition of oxaliplatin at first progression was better than a combination treatment using fluoropyrimidines and oxaliplatin with bevacizumab.In the sequential treatment, the escalation from fluoropyrimidines plus bevacizumab to fluoropyrimidines plus oxaliplatin with bevacizumab was recommended in case of progressive disease. Time to failure of strategy was the primary end-point, whereas the secondary end-points were overall survival, progression-free survival, overall response rate and safety.Three hundred patients with previously untreated metastatic colorectal cancer were randomised to receive either the sequential treatment (n = 151) or the combination treatment (n = 149). The sequential treatment was superior to the combination treatment about time to failure of strategy (15.2 months; 95% CI, 12.5-17.2 months vs. 7.8 months: 95% CI, 6.3-9.5 months; P < 0.001). However, the median overall survival was 27.5 (95% CI, 24.4 to 32.7) months in the sequential treatment and 27.0 (95% CI, 22.8 to 36.0) months in the combination treatment (hazard ratio, 0.92; 95% CI, 0.66 to 1.28; P = 0.61). The overall response rate was 33.1% in the sequential treatment arm and 51.7% in the combination treatment.The findings support the extension of the sequential treatment starting from fluoropyrimidine plus bevacizumab to selected patients who do not need an objective response to the threatening disease." @default.
• W4280591010 created "2022-05-22" @default.
• W4280591010 creator A5002171335 @default.
• W4280591010 creator A5010750105 @default.
• W4280591010 creator A5014061571 @default.
• W4280591010 creator A5016814013 @default.
• W4280591010 creator A5017789799 @default.
• W4280591010 creator A5025758494 @default.
• W4280591010 creator A5026639791 @default.
• W4280591010 creator A5041513590 @default.
• W4280591010 creator A5051559688 @default.
• W4280591010 creator A5055180271 @default.
• W4280591010 creator A5056915467 @default.
• W4280591010 creator A5076149190 @default.
• W4280591010 creator A5086205123 @default.
• W4280591010 date "2022-07-01" @default.
• W4280591010 modified "2023-10-16" @default.
• W4280591010 title "Phase 3 trial of sequential versus combination treatment in colorectal cancer: The C-cubed study" @default.
• W4280591010 cites W2016920426 @default.
• W4280591010 cites W2042149968 @default.
• W4280591010 cites W2071367057 @default.
• W4280591010 cites W2098354753 @default.
• W4280591010 cites W2102601598 @default.
• W4280591010 cites W2117355364 @default.
• W4280591010 cites W2120009106 @default.
• W4280591010 cites W2122152991 @default.
• W4280591010 cites W2129998117 @default.
• W4280591010 cites W2134373354 @default.
• W4280591010 cites W2135656951 @default.
• W4280591010 cites W2137417501 @default.
• W4280591010 cites W2139168548 @default.
• W4280591010 cites W2142436044 @default.
• W4280591010 cites W2143341124 @default.
• W4280591010 cites W2156147330 @default.
• W4280591010 cites W2162315065 @default.
• W4280591010 cites W2167138718 @default.
• W4280591010 cites W2168579528 @default.
• W4280591010 cites W2413389097 @default.
• W4280591010 cites W2671324896 @default.
• W4280591010 cites W2899140013 @default.
• W4280591010 cites W2916085177 @default.
• W4280591010 doi "https://doi.org/10.1016/j.ejca.2022.04.009" @default.
• W4280591010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35569283" @default.
• W4280591010 hasPublicationYear "2022" @default.
• W4280591010 type Work @default.
• W4280591010 citedByCount "0" @default.
• W4280591010 crossrefType "journal-article" @default.
• W4280591010 hasAuthorship W4280591010A5002171335 @default.
• W4280591010 hasAuthorship W4280591010A5010750105 @default.
• W4280591010 hasAuthorship W4280591010A5014061571 @default.
• W4280591010 hasAuthorship W4280591010A5016814013 @default.
• W4280591010 hasAuthorship W4280591010A5017789799 @default.
• W4280591010 hasAuthorship W4280591010A5025758494 @default.
• W4280591010 hasAuthorship W4280591010A5026639791 @default.
• W4280591010 hasAuthorship W4280591010A5041513590 @default.
• W4280591010 hasAuthorship W4280591010A5051559688 @default.
• W4280591010 hasAuthorship W4280591010A5055180271 @default.
• W4280591010 hasAuthorship W4280591010A5056915467 @default.
• W4280591010 hasAuthorship W4280591010A5076149190 @default.
• W4280591010 hasAuthorship W4280591010A5086205123 @default.
• W4280591010 hasBestOaLocation W42805910101 @default.
• W4280591010 hasConcept C121608353 @default.
• W4280591010 hasConcept C126322002 @default.
• W4280591010 hasConcept C141071460 @default.
• W4280591010 hasConcept C143998085 @default.
• W4280591010 hasConcept C203092338 @default.
• W4280591010 hasConcept C207103383 @default.
• W4280591010 hasConcept C2776694085 @default.
• W4280591010 hasConcept C2776999253 @default.
• W4280591010 hasConcept C2777802072 @default.
• W4280591010 hasConcept C2780962732 @default.
• W4280591010 hasConcept C44249647 @default.
• W4280591010 hasConcept C526805850 @default.
• W4280591010 hasConcept C535046627 @default.
• W4280591010 hasConcept C71924100 @default.
• W4280591010 hasConcept C90924648 @default.
• W4280591010 hasConceptScore W4280591010C121608353 @default.
• W4280591010 hasConceptScore W4280591010C126322002 @default.
• W4280591010 hasConceptScore W4280591010C141071460 @default.
• W4280591010 hasConceptScore W4280591010C143998085 @default.
• W4280591010 hasConceptScore W4280591010C203092338 @default.
• W4280591010 hasConceptScore W4280591010C207103383 @default.
• W4280591010 hasConceptScore W4280591010C2776694085 @default.
• W4280591010 hasConceptScore W4280591010C2776999253 @default.
• W4280591010 hasConceptScore W4280591010C2777802072 @default.
• W4280591010 hasConceptScore W4280591010C2780962732 @default.
• W4280591010 hasConceptScore W4280591010C44249647 @default.
• W4280591010 hasConceptScore W4280591010C526805850 @default.
• W4280591010 hasConceptScore W4280591010C535046627 @default.
• W4280591010 hasConceptScore W4280591010C71924100 @default.
• W4280591010 hasConceptScore W4280591010C90924648 @default.
• W4280591010 hasLocation W42805910101 @default.
• W4280591010 hasLocation W42805910102 @default.
• W4280591010 hasOpenAccess W4280591010 @default.
• W4280591010 hasPrimaryLocation W42805910101 @default.
• W4280591010 hasRelatedWork W2003080165 @default.
• W4280591010 hasRelatedWork W2051540233 @default.
• W4280591010 hasRelatedWork W2098707609 @default.

• next